Stock analysts at Jefferies Financial Group started coverage on shares of Kodiak Sciences (NASDAQ:KOD - Get Free Report) in a research report issued on Monday, Marketbeat.com reports. The firm set a "buy" rating and a $15.00 price target on the stock. Jefferies Financial Group's target price suggests a potential downside of 0.07% from the company's previous close.
Other equities research analysts have also recently issued research reports about the stock. HC Wainwright lifted their price target on shares of Kodiak Sciences from $3.00 to $5.00 and gave the company a "neutral" rating in a research note on Monday, August 18th. Barclays lifted their target price on shares of Kodiak Sciences from $4.00 to $7.00 and gave the company an "underweight" rating in a research report on Thursday, August 14th. Finally, JPMorgan Chase & Co. upgraded shares of Kodiak Sciences from an "underweight" rating to a "neutral" rating and set a $15.00 price target for the company in a research report on Thursday, August 14th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $10.50.
Check Out Our Latest Research Report on KOD
Kodiak Sciences Stock Up 57.5%
Shares of NASDAQ:KOD traded up $5.48 during trading on Monday, reaching $15.01. 5,717,645 shares of the company's stock traded hands, compared to its average volume of 422,223. Kodiak Sciences has a fifty-two week low of $1.92 and a fifty-two week high of $16.30. The company has a 50-day simple moving average of $8.60 and a 200-day simple moving average of $5.31. The firm has a market cap of $792.83 million, a PE ratio of -3.95 and a beta of 2.44.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.02). On average, equities research analysts forecast that Kodiak Sciences will post -3.45 EPS for the current year.
Hedge Funds Weigh In On Kodiak Sciences
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Headlands Technologies LLC grew its holdings in Kodiak Sciences by 256.4% in the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock valued at $30,000 after buying an additional 5,815 shares in the last quarter. US Bancorp DE grew its holdings in shares of Kodiak Sciences by 131.7% in the first quarter. US Bancorp DE now owns 9,282 shares of the company's stock valued at $26,000 after purchasing an additional 5,276 shares during the period. Vontobel Holding Ltd. acquired a new stake in Kodiak Sciences during the first quarter worth about $28,000. Public Employees Retirement System of Ohio increased its position in Kodiak Sciences by 183.9% during the fourth quarter. Public Employees Retirement System of Ohio now owns 14,759 shares of the company's stock worth $147,000 after purchasing an additional 9,560 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its stake in Kodiak Sciences by 21.7% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company's stock worth $56,000 after purchasing an additional 2,691 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.
About Kodiak Sciences
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Further Reading
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.